查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
Bcma 针对治疗市场，按类型、癌症、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测
市场调查报告书
商品编码
1419021

Bcma 针对治疗市场，按类型、癌症、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Bcma Targeted Therapies Market, By Type, By Cancer, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 299 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2023 年 Bcma 标靶治疗市场规模为 90.1 亿美元，2024 年至 2032 年CAGR为 20.5%。

Bcma 标靶治疗市场-市场动态

多发性骨髓瘤復发病例数量的增加预计将推动 B 细胞成熟抗原 (BCMA) 标靶治疗市场的成长

BCMA标靶治疗，例如标靶治疗，透过专门关注表达BCMA的癌细胞，提供了更精确的方法。这种方法有可能带来更有效、危害较小的治疗方法，从而解决未满足的医疗需求。据美国临床肿瘤学会称，到 2023 年，美国估计将有 35,730 名成年人（19,860 名男性和 15,870 名女性）被诊断出患有多发性骨髓瘤。 2020 年，全球估计有176,404 人被诊断出患有多发性骨髓瘤。此外，在理解多发性骨髓瘤的分子和遗传基础方面不断取得的进展可能会导致新治疗靶点的确定和更有效的BCMA标靶疗法的开发。然而，值得注意的是，这些疗法的高成本可能会阻碍市场成长。

Bcma 标靶治疗市场 - 关键见解

  • 根据我们的研究分析师分享的分析，预计全球 Bcma 标靶治疗市场在预测期内（2024-2032 年）每年将以 20.5% 左右的CAGR成长
  • 根据类型细分，预计嵌合抗原受体 T 细胞将在 2023 年显示最大的市场份额
  • 根据最终用户细分，医院是 2023 年的领先类型
  • 按地区划分，北美是 2023 年的主要收入来源

Bcma 标靶治疗市场-細項分析：

全球 Bcma 标靶治疗市场根据类型、癌症、最终用户和地区进行细分。

市场根据类型分为三类：双特异性抗体、抗体药物偶联物和嵌合抗原受体 T 细胞。此市场主要由嵌合抗原受体 T 细胞领域主导。多发性骨髓瘤细胞是一种影响浆细胞的癌症，在其表面表达一种称为 BCMA 的蛋白质。 CAR-T细胞疗法是一种免疫疗法，涉及修改患者自身的T细胞以表达能够识别和攻击癌细胞的嵌合抗原受体（CAR）。

根据癌症类型，市场分为三类：肝癌、呼吸道癌、脑癌和其他癌症。 B 细胞成熟抗原 (BCMA) 标靶疗法主要用于治疗多发性骨髓瘤，这是一种影响浆细胞的癌症。 BCMA 存在于多发性骨髓瘤细胞的表面，这使其成为治疗介入的主要目标。

根据最终用户，市场分为两类：医院和癌症研究所。市场主要由医院部门控制。为了改善患者护理和支援服务，医院可能必须专注于管理 BCMA 标靶治疗的潜在副作用，并为接受治疗的患者提供全面护理。对于医院来说，遵守癌症治疗管理的监管要求、确保方案符合卫生当局製定的安全性和有效性标准至关重要。

Bcma 标靶治疗市场 - 地理洞察

从地理来看，该市场遍布北美、拉丁美洲、欧洲、亚太、中东和非洲等多个地区。这些区域根据参与商业活动的国家进一步划分。预计该市场的成长将由北美主导，这主要是由于对多发性骨髓瘤创新疗法的研发投资不断增加。美国是临床研究的主要中心，对包括多发性骨髓瘤在内的各种疾病进行了大量的临床试验。着名研究机构、学术医疗中心和生物技术公司的存在为临床试验提供了强大的基础设施，从而促进了新疗法的开发。根据国家卫生支出数据，美国医疗卫生研发投入大幅增长，2020年达到2451亿美元，较2019年增长11.1%。- 私部门研发系统在2020 年发生了变化，可能受到对COVID-19 大流行的反应和影响的影响。

Bcma 标靶治疗市场-竞争格局：

BCMA 标靶疗法市场的特点是竞争格局动态，许多製药和生物技术公司积极参与这些疗法的开发。这些疗法已证明在治疗多发性骨髓瘤方面具有临床有效性，特别是对于復发或对其他治疗方案表现出抗药性的患者。许多公司目前都参与开发 BCMA 标靶疗法的临床前和临床阶段，无论是作为独立疗法还是与其他药物合併使用。例如，2023年1月31日，专门从事细胞和基因治疗的临床阶段公司Poseida Therapeutics, Inc.宣布Eric Ostertag博士辞去执行主席职务并退休董事会任命，于2023 年2 月3 日生效。不过，Ostertag 博士将继续作为顾问为公司做出贡献，提供技术和科学事务的宝贵专业知识。

最近的发展：

2022 年 11 月 17 日，预计到 2040 年，全球将出现超过 275,000 例多发性骨髓瘤新病例。多发性骨髓瘤是一种血癌，其特征是通常起源于骨髓的恶性浆细胞增殖。 B 细胞成熟抗原 (BCMA) 是一种重要的细胞表面抗原，几乎存在于所有多发性骨髓瘤病例中，但在浆细胞以外的正常组织中表达有限。这使其成为多发性骨髓瘤治疗的关键标靶。

目录

第 1 章：Bcma 标靶治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • Bcma 标靶治疗市场片段（按类型）
    • Bcma 癌症标靶治疗市场片段
    • Bcma 标靶治疗市场片段（按最终用户）
    • Bcma 标靶治疗市场片段（按国家/地区）
    • Bcma 标靶治疗市场片段（按地区）
  • 竞争洞察

第 3 章：Bcma 标靶治疗主要市场趋势

  • Bcma 标靶治疗市场驱动因素
    • 市场驱动因素的影响分析
  • Bcma 标靶治疗市场限制
    • 市场限制影响分析
  • Bcma 标靶治疗市场机会
  • Bcma标靶治疗市场未来趋势

第 4 章：Bcma 标靶治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：Bcma 标靶治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：Bcma 标靶治疗市场格局

  • Bcma 标靶治疗市场占有率分析，2023 年
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：Bcma 标靶治疗市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 双特异性抗体
    • 抗体药物偶联物
    • 嵌合抗原受体 T 细胞

第 8 章：Bcma 标靶治疗市场 - 按癌症分类

  • 概述
    • 按癌症分类的细分市场占有率分析
    • 肝癌
    • 呼吸道癌
    • 脑癌
    • 其他的

第 9 章：Bcma 标靶治疗市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 癌症研究所

第 10 章：Bcma 标靶治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • Bcma 标靶治疗北美主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按类型）
    • 北美市场规模与预测（按癌症）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • Bcma 标靶治疗欧洲主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模与预测（按癌症）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • Bcma 标靶治疗亚太地区主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区癌症市场规模与预测
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • Bcma 标靶治疗拉丁美洲主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（按癌症）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • Bcma 标靶治疗中东和非洲主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按类型）
    • 中东和非洲市场规模及预测（按癌症）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - Bcma 标靶治疗产业

  • 竞争仪表板
  • 公司简介
    • Transposagen Biopharmaceuticals
    • Sutro Biopharma
    • Malin Corporation
    • Eureka Therapeutics
    • firstVentury Equity
    • Five Prime Therapeutics
    • Credit Suisse Securities
    • Dana-Farber Cancer Institute
    • Deerfield Partners
    • Onyx Pharmaceuticals
    • Juno Therapeutics

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV2086

REPORT HIGHLIGHT

Bcma Targeted Therapies Market size was valued at USD 9,010 Million in 2023, expanding at a CAGR of 20.5% from 2024 to 2032.

BCMA, or B cell maturation antigen, has emerged as a promising treatment target for multiple myeloma (MM) due to its highly specific expression in malignant plasma cells (PCs). Various BCMA-targeted therapies, such as antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have shown remarkable clinical responses in patients with relapsed and refractory MM. The introduction of novel therapeutics like proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has further enhanced the treatment outcomes for patients with MM. It is estimated that there will be over 275,000 new cases of multiple myeloma worldwide by 2040. Multiple myeloma is a type of blood cancer characterized by the abnormal proliferation of malignant plasma cells, primarily originating in the bone marrow. BCMA, a cell surface antigen predominantly found in multiple myeloma cases, presents a valuable target for therapeutic interventions in this disease.

Bcma Targeted Therapies Market- Market Dynamics

Increasing number of recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market

BCMA-targeted therapies, such as targeted treatments, provide a more precise method by specifically focusing on cancer cells that express BCMA. This approach has the potential to result in treatments that are more effective and less harmful, thereby addressing the unmet medical requirements. According to the American Society of Clinical Oncology, In 2023, an estimated 35,730 adults (19,860 men and 15,870 women) in the United States will be diagnosed with multiple myeloma. Worldwide, an estimated 176,404 people were diagnosed with multiple myeloma in 2020. Additionally, ongoing advancements in comprehending the molecular and genetic foundations of multiple myeloma may lead to the identification of new therapeutic targets and the development of more potent BCMA-targeted therapies. However, it is important to note that the high cost of these therapies may hinder market growth.

Bcma Targeted Therapies Market- Key Insights

  • As per the analysis shared by our research analyst, the global Bcma Targeted Therapies market is estimated to grow annually at a CAGR of around 20.5% over the forecast period (2024-2032)
  • Based on Type segmentation, Chimeric Antigen Receptor T-Cells was predicted to show maximum market share in the year 2023
  • Based on End-User segmentation, Hospitals was the leading type in 2023
  • On the basis of region, North America was the leading revenue generator in 2023

Bcma Targeted Therapies Market- Segmentation Analysis:

The Global Bcma Targeted Therapies Market is segmented on the basis of Type, Cancer, End-User, and Region.

The market is divided into three categories based on Type: Bispecific Antibodies, Antibody Drug Conjugates and Chimeric Antigen Receptor T-Cells.The market is largely dominated by the segment of Chimeric Antigen Receptor T-Cells. Multiple myeloma cells, which are a type of cancer that affects plasma cells, express a protein called BCMA on their surface. CAR-T cell therapy is an immunotherapy approach that involves modifying the patient's own T cells to express a chimeric antigen receptor (CAR) capable of identifying and attacking cancer cells.

The market is segmented into three groups according to the type of cancer: Liver Cancer, Respiratory Cancer, Brain Cancer, and Others. B-Cell Maturation Antigen (BCMA) targeted therapies have mainly been used in the treatment of multiple myeloma, a form of cancer that impacts plasma cells. BCMA is present on the surface of multiple myeloma cells, which makes it a prime target for therapeutic interventions.

The market is divided into two categories based on End-User: Hospitals and Cancer Research Institute. The market is largely controlled by the hospitals sector. In order to improve patient care and support services, hospitals may have to focus on managing the potential side effects of BCMA-targeted therapies and providing comprehensive care for patients receiving treatment. It is crucial for hospitals to comply with regulatory requirements for the administration of cancer treatments, ensuring that protocols are in line with the safety and efficacy standards set by health authorities.

Bcma Targeted Therapies Market- Geographical Insights

Geographically, this market is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increasing investments in research and development of innovative therapies for multiple myeloma. The United States serves as a major center for clinical research, hosting numerous clinical trials for various diseases, including multiple myeloma. The presence of renowned research institutions, academic medical centers, and biotechnology companies contributes to a strong infrastructure for conducting clinical trials, thereby facilitating the development of new therapies. According to the National Health Expenditures, the United States (U.S.) witnessed a significant increase in medical and health research and development (R&D) investment, reaching USD 245.1 billion in 2020, marking an 11.1% rise from 2019. The growth rates in the public-private sector R&D ecosystem underwent changes in 2020, likely influenced by the response to and impact of the COVID-19 pandemic.

Bcma Targeted Therapies Market- Competitive Landscape:

The BCMA-targeted therapies market is characterized by a dynamic competitive landscape, with numerous pharmaceutical and biotechnology companies actively engaged in the development of these treatments. These therapies have demonstrated clinical effectiveness in addressing multiple myeloma, particularly in patients who have relapsed or shown resistance to other treatment options. Many companies are currently involved in both preclinical and clinical stages of developing BCMA-targeted therapies, either as standalone treatments or in combination with other drugs. As an example, on January 31, 2023, Poseida Therapeutics, Inc., a clinical-stage company specializing in cell and gene therapy, announced the resignation of Dr. Eric Ostertag, M.D., Ph.D., as Executive Chairman and his retirement from the Board of Directors, effective February 3, 2023. However, Dr. Ostertag will continue to contribute to the company as a consultant, providing valuable expertise in technical and scientific matters.

Recent Developments:

November 17, 2022, More than 275,000 new cases of multiple myeloma are expected to occur globally by the year 2040. Multiple myeloma is a blood cancer characterized by the proliferation of malignant plasma cells that typically originate in the bone marrow. B-cell maturation antigen (BCMA) is an important cell surface antigen found in nearly all cases of multiple myeloma, but with limited expression on normal tissues other than plasma cells. This makes it a key target for multiple myeloma therapeutics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BCMA TARGETED THERAPIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Transposagen Biopharmaceuticals
  • Sutro Biopharma
  • Malin Corporation
  • Eureka Therapeutics
  • firstVentury Equity
  • Five Prime Therapeutics
  • Credit Suisse Securities
  • Dana-Farber Cancer Institute
  • Deerfield Partners
  • Onyx Pharmaceuticals
  • Juno Therapeutics

GLOBAL BCMA TARGETED THERAPIES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Bispecific Antibodies
  • Antibody Drug Conjugates
  • Chimeric Antigen Receptor T-Cells

GLOBAL BCMA TARGETED THERAPIES MARKET, BY CANCER- MARKET ANALYSIS, 2019 - 2032

  • Liver Cancer
  • Respiratory Cancer
  • Brain Cancer
  • Others

GLOBAL BCMA TARGETED THERAPIES MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Research Institute

GLOBAL BCMA TARGETED THERAPIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bcma Targeted Therapies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bcma Targeted Therapies Market Snippet by Type
    • 2.1.2. Bcma Targeted Therapies Market Snippet by Cancer
    • 2.1.3. Bcma Targeted Therapies Market Snippet by End-User
    • 2.1.4. Bcma Targeted Therapies Market Snippet by Country
    • 2.1.5. Bcma Targeted Therapies Market Snippet by Region
  • 2.2. Competitive Insights

3. Bcma Targeted Therapies Key Market Trends

  • 3.1. Bcma Targeted Therapies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bcma Targeted Therapies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bcma Targeted Therapies Market Opportunities
  • 3.4. Bcma Targeted Therapies Market Future Trends

4. Bcma Targeted Therapies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bcma Targeted Therapies Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bcma Targeted Therapies Market Landscape

  • 6.1. Bcma Targeted Therapies Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bcma Targeted Therapies Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Bispecific Antibodies
    • 7.1.3. Antibody Drug Conjugates
    • 7.1.4. Chimeric Antigen Receptor T-Cells

8. Bcma Targeted Therapies Market - By Cancer

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer, 2023 & 2032 (%)
    • 8.1.2. Liver Cancer
    • 8.1.3. Respiratory Cancer
    • 8.1.4. Brain Cancer
    • 8.1.5. Others

9. Bcma Targeted Therapies Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Cancer Research Institute

10. Bcma Targeted Therapies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bcma Targeted Therapies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bcma Targeted Therapies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bcma Targeted Therapies Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bcma Targeted Therapies Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bcma Targeted Therapies Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bcma Targeted Therapies Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Transposagen Biopharmaceuticals
    • 11.2.2. Sutro Biopharma
    • 11.2.3. Malin Corporation
    • 11.2.4. Eureka Therapeutics
    • 11.2.5. firstVentury Equity
    • 11.2.6. Five Prime Therapeutics
    • 11.2.7. Credit Suisse Securities
    • 11.2.8. Dana-Farber Cancer Institute
    • 11.2.9. Deerfield Partners
    • 11.2.10. Onyx Pharmaceuticals
    • 11.2.11. Juno Therapeutics

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Bcma Targeted Therapies Market: Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Bcma Targeted Therapies Market, by Type 2019-2032 (USD Million)
  • TABLE Bcma Targeted Therapies Market: Cancer Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Cancer
  • TABLE Global Bcma Targeted Therapies Market, by Cancer 2019-2032 (USD Million)
  • TABLE Bcma Targeted Therapies Market: End-User Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by End-User
  • TABLE Global Bcma Targeted Therapies Market, by End-User 2019-2032 (USD Million)
  • TABLE Bcma Targeted Therapies Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Bcma Targeted Therapies Market, by Region 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)